Aptose Biosciences

Aptose Biosciences, Inc. is a clinical-stage oncology company, which engages in the discovery, research, and development of anti-cancer therapies. Its product pipeline includes APTO-253, a small molecule that induces expression of the Kruppel-Like Factor 4 genes; and CG-806 a non-covalent small molecule therapeutic agent. The company was founded on September 5, 1986 and is headquartered in Toronto, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO and TORONTO, June 27, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the appointment of Mr. Fletcher Payne to the position of Senior Vice President, Chief Financial Officer (CFO). In this role, Mr. Payne will lead Aptose's financial operations and serve as a member of the Company's executive management team.

Aptose Appoints Fletcher Payne as Senior Vice President, Chief Financial Officer

HM43239 Delivers New Complete Remission at 160mg Dose in AML with Wildtype FLT3

CORRECTION -- Aptose Presents Highlights from Corporate Update and KOL Event

Aptose Presents Highlights from Corporate Update and KOL Event

SAN DIEGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced the voting results from the Company's annual and special meeting of shareholders held today, May 31, 2022 (the “Meeting”). A total of 53.46% of the common shares of the Company entitled to be voted were represented by shareholders present or represented by proxy at the Meeting.

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Clinical Updates for HM43239 and Luxeptinib

Aptose to Hold KOL Event and Corporate Update Thursday, June 2nd

Aptose Biosciences Inc. (NASDAQ:APTO ) Q1 2022 Earnings Conference Call May 9, 2022 5:00 PM ET Company Participants Dr. William G. Rice – Chairman, President and Chief Executive Officer Dr. Rafael Bejar – Senior Vice President and Chief Medical Officer Dan Ferry – Managing Director, LifeSci Advisors LLC Conference Call Participants Gregory Renza – RBC Capital Markets Matthew Biegler – Oppenheimer & Co. Inc. Li Watsek – Cantor Fitzgerald Matthew Cross – Allegiance Global Partners Operator Welcome to the Aptose Biosciences o Incorporated Reports Result for the First Quarter 2022 Conference Call.

Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q1 2022 Results - Earnings Call Transcript

Aptose Reports Results for the First Quarter 2022

SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HM43239, an oral, myeloid kinome inhibitor, for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation. Currently, an international Phase 1/2 clinical trial is ongoing for HM43239 in the R/R AML patient population. HM43239 received orphan drug designation from the FDA for treatment of acute myeloid leukemia in 2018.

Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation

SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that Dr. William G. Rice, Chairman, President and CEO of Aptose, will participate in the RBC Capital Markets Global Healthcare Conference:

Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference

Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib Three Recent Peer-reviewed Journal Articles Reflect Distinctive Properties of Luxeptinib

Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation

SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the quarter ended March 31, 2022, on Monday, May 9, 2022 after the close of the market, and provide a corporate update.

Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022

─ Appoints Philippe Ledru as Chief Commercial Officer ─

Aptose Announces Executive Management Changes

SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in a panel to discuss new approaches of treating acute myeloid leukemias (AML) at Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference:

Aptose to Present at Canaccord Genuity's 2022 Horizons in Oncology Virtual Conference

Aptose Biosciences Inc. (APTO) CEO Dr. William G. Rice on Q4 2021 Results - Earnings Call Transcript

- HM43239 clinical remission at 120mg expands list of potential treatable AML populations -

Aptose Reports Results for the Fourth Quarter and Full Year 2021

SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, will report financial results for the year and quarter ended December 31, 2021, on Tuesday, March 22, 2022 after the close of the market, and provide a corporate update.

Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022

SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will present and host one-on-one meetings at Oppenheimer's 32nd Annual Healthcare Conference:

Aptose to Present at Oppenheimer's 32nd Annual Healthcare Conference

Celularity

CNS Pharmaceuticals

Celyad

Spruce Biosciences

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

5 Beaten-Down Biotech Bets to Bounce Back in 2022

— H.C. Wainwright BIOCONNECT Virtual Conference —

Aptose to Participate in Two Biotech Events in January 2022

Aptose Biosciences Inc (NASDAQ: APTO) will discontinue further clinical development of APTO-253 in hematologic malignancies and solid tumors.  The decision follows the prioritization of the Company's other more advanced pipeline candidates, as well as an internal review of APTO-253, including an FDA clinical hold.

Aptose Shares Fall After Ceasing APTO-253 Program

-- Clinical development of the MYC repressor APTO-253 will be discontinued -- -- Company will focus on advancing kinome inhibitor pipeline --

Aptose Provides Update on APTO-253 Program

Aptose Biosciences Inc (NASDAQ: APTO) presented data from the ongoing Phase 1/2 study of HM43239 in patients relapsed or refractory acute myeloid leukemia (AML) who had received at least one prior line of therapy. Data were presented at the American Society of Hematology (ASH) Annual meeting.

Aptose Shares Fall After HM43239 Data Featured At ASH Annual Meeting, Luxeptinib, APTO-253 Update

HM43 239 Data Featured in Oral Presentation at the  American Society of Hematology Annual Meeting

HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

HM43239 clinical update in AML after oral presentation at 2021 ASH Annual Meeting Luxeptinib clinical update in AML and B-cell cancers

Aptose to Hold Corporate Update Monday, December 13th

Investors need to pay close attention to Aptose Biosciences (APTO) stock based on the movements in the options market lately.

News for Aptose Biosciences Stock (APTO)